Présentation de l'entreprise
enVVeno Medical Corporation, trading under the ticker NVNO, operates as a clinical-stage medical device company dedicated to the development of bioprosthetic tissue-based solutions designed to enhance the standard of care in the treatment of venous disease. The corporation's primary focus lies in the healthcare sector, specifically within the medical devices industry, where it aims to provide innovative replacements for venous valves to address venous disease conditions. As of the latest available data, the company maintains a market capitalization of $6.77 million and employs a workforce of 33 individuals to execute its clinical development strategy. These valuation and employment figures indicate that enVVeno is a micro-cap entity with limited financial scale, reflecting its status as a pre-revenue or early-stage development company that has not yet generated significant commercial sales to justify a larger market valuation or revenue base.
Santé financière
The company's financial statements for the trailing twelve months (TTM) show no reported revenue and a net income of $-19,472,000, while the EBITDA stands at $-20,763,000. The substantial gap between the zero revenue and the significant negative net income reveals a cost structure dominated by research and development expenses and operational overheads rather than cost of goods sold, which is consistent with a clinical-stage firm lacking commercial product sales. Free cash flow for the period is reported at $-9,209,875, indicating that the company is consuming cash reserves to fund its operations and development pipeline rather than generating liquidity from business activities. All three key margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which indicates that without commercial revenue, the traditional efficiency measures derived from sales cannot be calculated or are effectively null. On the balance sheet, the company holds $28.21 million in cash against total debt of $700,000, resulting in a debt-to-equity ratio of 2.58, suggesting a capital structure that relies heavily on equity financing while maintaining a relatively low absolute debt load. The current ratio is 13.58, a figure that indicates an exceptionally high level of short-term liquidity relative to current liabilities, providing a substantial buffer against immediate financial obligations. Furthermore, the return on equity is -56.2% and the return on assets is -35.1%, metrics that reveal that management is currently diluting shareholder value and asset base through significant losses incurred during the clinical development phase rather than generating returns.
Évaluation de la valorisation
The trailing twelve-month P/E ratio is listed as N/A due to the lack of earnings, while the forward P/E is reported as -8.68, a negative figure that implies the market is pricing in future earnings expectations that are currently undefined or negative. The price-to-book ratio stands at 0.25, indicating that the market values the company at a significant discount to its net book value, which is typical for capital-intensive or loss-making biotech firms where asset values may not fully reflect intangible development potential. Alternative valuation metrics such as the price-to-sales ratio are N/A because there is no sales data, and the EV/EBITDA ratio is 1.00, a low multiple that reflects the company's negative earnings and cash generation relative to its enterprise value. The stock has experienced extreme price volatility within the past year, trading between a 52-week low of $8.67 and a 52-week high of $196.70, meaning the current share price sits at a level that reflects the uncertainty surrounding its clinical milestones and regulatory approvals. With a beta of 1.09, the stock exhibits price volatility that is slightly higher than the broader market, suggesting that investor sentiment towards enVVeno's specific development risks amplifies standard market movements.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet achieved commercial revenue to calculate meaningful growth rates against a prior period. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, which explains that enVVeno reinvests all available capital and retained earnings into its clinical trials and product development rather than distributing income to shareholders. This non-dividend profile is standard for clinical-stage medical device companies that must prioritize funding their pipeline to achieve market entry and profitability. Consequently, the overall growth and income profile of enVVeno is characterized by a complete reliance on future clinical success and regulatory approval to transition from a cash-burning entity to a revenue-generating business, with no current income generation or historical growth trajectory to analyze.